

TO THE EDITOR:

JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics

Thomas McKerrell,¹⁻³ Naomi Park,¹ Jianxiang Chi,^{4,5} Grace Collord,¹ Thaidy Moreno,⁶ Hannes Ponstingl,¹ Joao Dias,⁷ Petroula Gerasimou,^{4,5} Kiki Melanthiou,⁸ Chrystalla Prokopiou,⁹ Marios Antoniadis,⁸ Ignacio Varela,⁶ Paul A. Costeas,^{4,5} and George S. Vassiliou¹⁻⁴

¹The Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom; ²Department of Haematology, University of Cambridge, Cambridge, United Kingdom; ³Department of Haematology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom; ⁴The Center for the Study of Haematological Malignancies, Nicosia, Cyprus; ⁵The Karaïskakio Foundation, Nicosia, Cyprus; ⁶Instituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain; ⁷Cancer Molecular Diagnosis Laboratory, National Institute for Health Research Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom; ⁸Department of Haematology, Nicosia General Hospital, Nicosia, Cyprus; and ⁹Department of Haematology, Limassol General Hospital, Limassol, Cyprus

The *JAK2* V617F mutation is the most common somatic mutation in the classical myeloproliferative neoplasms (MPNs), present in >95% of cases of polycythemia vera (PV) and ~50% of essential thrombocythemia (ET) and myelofibrosis (MF).¹⁻⁴ It is usually the sole identifiable driver mutation in MPNs⁵ and was recently also identified as a driver of age-related clonal hemopoiesis in healthy individuals.⁶⁻⁹ In order to investigate the preclinical clonal evolution of MPNs, we identified 12 individuals with a *JAK2* V617F mutant MPN, who 4.6 to 15.2 years previously (median 10.2 years) had also donated blood to register with the Cyprus Bone Marrow Donor Registry at the Karaïskakio Foundation (Table 1; Figure 1A).

First, we interrogated all 24 samples for 15 myeloid mutation hot spots including *JAK2* V617 (supplemental Table 1), using a previously described multiplex polymerase chain reaction/MiSeq sequencing protocol that reliably detects nucleotide substitutions present at a VAF ≥ 0.008 .⁶ Additionally, for 12 samples with sufficient DNA available, we performed targeted DNA capture for all exons of 41 genes recurrently mutated in myeloid neoplasms (supplemental Table 2) using targeted capture with custom RNA baits (SureSelect, Agilent Technologies ELID ID: 0735431) followed by sequencing on Illumina HiSeq 2500. Substitutions and indels were identified and quantified using Mutation Identification and Analysis Software as described.^{6,10} Finally, we genotyped archival registry samples for rs12343867, a single nucleotide polymorphism (C/T) linked to the *JAK2* 46/1 haplotype and polymorphisms at the *TERT*, *SH2B3*, *TET2*, *MECOM*, and *MYB* genes that are associated with a predisposition to MPN.^{11,12} The study was approved by the Cyprus National Bioethics Committee (EEBK/EII/2014/11) and performed in accordance with the Declaration of Helsinki.

Amplicon sequencing returned a median coverage of 6641 reads per nucleotide at the studied hot spots (excluding *NPM1* exon 12). This confirmed the presence of *JAK2* V617F in all 12 diagnostic and 9 of 12 archival samples (supplemental Table 3). The remaining 3 samples were *JAK2* V617F negative at the sensitivity of our assay (VAF ≥ 0.008). The only other hot spot mutation identified was *SRSF2* P95R in patient P3 (see later). Pull-down sequencing of all exons of 41 genes from 12 samples with sufficient DNA returned an average coverage of 1978 reads per nucleotide and showed a close correlation in VAF quantitation for both *JAK2* V617F and *SRSF2* P95R with amplicon sequencing (supplemental Table 3).

The *JAK2* V617F VAF at MPN diagnosis differed between patients as expected¹³; however, the average rate of clonal growth also varied widely, ranging from 0.36% to 6.2% per annum (Figure 1B). Targeted exon capture from 12 of 24 samples only identified 1 co-mutation with a VAF >0.02, *SRSF2* P95R in patient P3 who had a diagnosis of MF (supplemental Table 3). As this locus was also studied by amplicon sequencing, we were able to quantify the *SRSF2* P95R VAF in both the diagnostic and the archival sample taken 12.6 years earlier. The MPN diagnostic sample VAFs for *JAK2* V617F and *SRSF2* P95R were similar (0.37 and 0.41, respectively; supplemental Tables 3 and 4) indicating that they co-occurred in most cells of the neoplastic clone. However, the archival sample did not harbor *JAK2* V617F (or did so at a level below the sensitivity of our assay) but did harbor the *SRSF2* P95R at a VAF of 0.06 indicating this was the clone-founding mutation.

Table 1. Participant characteristics

Patient ID	Age at MPN diagnosis (y)	Sex	Diagnosis	WBC count ($\times 10^6/L$)	Hb (g/L)	Platelet count ($\times 10^6/L$)	Time between samples (y)
P1	53.6	F	PV	17.3	194	550	10.1
P2	24.2	F	PV	n/a	n/a	n/a	5.5
P3	53.4	F	MF	4.2	112	130	12.6
P4	24.5	M	ET	8.4	15.6	600	4.6
P5	58.7	F	ET	8.94	142	637	14.5
P6	40.6	F	PV	7.7	168	602	6.8
P7	68.2	M	MF	8.1	81	74	15.2
P8	33	M	ET	10.3	149	776	12.1
P9	43.2	M	ET	12.1	148	793	9.4
P10	66.9	F	PV	7.6	154	830	14.7
P11	58.4	M	PV	12.7	220	423	10.3
P12	27	F	ET	5.1	135	750	4.6

F, female; Hb, hemoglobin concentration; M, male; MF, idiopathic myelofibrosis; n/a, not available; WBC, white blood cell.

We and others reported that *JAK2* V617F was a common driver of clonal hematopoiesis⁶⁻⁹; however, although *JAK2* V617F clonal hematopoiesis is likely to be the ancestor of most MPNs, our understanding of the latency and rate of clonal expansion of *JAK2* V617F-positive clones are not well understood. Our findings demonstrate that although additional driver mutations can accelerate preclinical clonal expansion of *JAK2* V617F clones, the process is highly variable even between individuals whose clones harbor *JAK2* V617F as the sole identifiable driver and who represent the majority of MPN patients.¹⁴

A recent study used ultrasensitive sequencing to show that clonal hematopoiesis driven by acute myeloid leukemia (AML)-associated mutations was ubiquitous among healthy adults aged 50 to 60 years.¹⁵ Interestingly, most clones identified in this study were associated with loss-of-function mutations in *DNMT3A* and *TET2*, and although most persisted over long periods (>10 years), they usually exhibited only modest expansion if any. However, in contrast to studies looking at larger numbers of people with lower assay sensitivities,⁶⁻⁹ this study did not identify *JAK2* mutant clones in any of its 20 participants.¹⁵ It is therefore possible that *JAK2* V617F, a hot spot mutation that relies on a G>T transversion that is uncommon in myeloid malignancies,¹⁶ is acquired less often but has a more pronounced effect on clonal growth than many other mutations. Nevertheless, it should be noted that the high rates of clonal growth in our study were observed in individuals that (1) were younger than the average MPN patient (as they were identified because they were registered stem cell donors) and (2) did actually go on to develop MPN and are therefore unlikely to be characteristic of the general behavior of *JAK2* V617F clones. Additionally, there is a possibility that some of these clones may not have been the same from clonal hematopoiesis to MPN diagnosis, as MPN patients can sometimes harbor >1 *JAK2* V617F clone.¹⁷ Nevertheless, clonal expansion rates varied dramatically even among the 12 individuals studied here. As certain germ line polymorphisms are associated with an increased risk of developing both *JAK2* V617F-driven clonal hematopoiesis and MPN,^{11,12,17,18} we genotyped our patients for these (supplementary Table 4). In our small group of patients, we observed a possible association between the *JAK2* 46/1 risk haplotype (C) and the average annual rise in *JAK2* V617F VAF. In

fact, the 4 fastest-expanding clones were either CC homozygous in the germ line (P2 and P4) or through somatic loss of heterozygosity (P1), or had a second driver mutation (P3). These observations suggest that the 46/1 haplotype may influence the rate of expansion of established *JAK2* V617F mutant clones and that loss of heterozygosity involving the risk haplotype may further expedite clonal expansion. These findings need to be verified in larger studies.

Interestingly, 1 of our patients acquired *JAK2* V617F after *SRSF2* p95R, and this was followed by a clonal sweep and the development of MF >12 years later. Clonal hematopoiesis driven by mutant *SRSF2* is very rare before the age of 70 years,⁶ yet this individual harbored a significant *SRSF2* P95R clone (VAF 0.06) aged only 40 years old. A recent study of 182 MF patients identified many with *JAK2* V617F and *SRSF2* P95 co-mutation, including several aged <70 years ($n = 21$, age range 39-84 years).¹⁹ Taken together, these observations suggest that younger individuals with *SRSF2*-mutant clonal hematopoiesis may be at a high risk of progression to a hematological neoplasm.

Our study demonstrates that *JAK2* V617F neoplasms develop from clonal hematopoiesis over many years, sometimes over more than a decade. Although co-mutations in other myeloid genes may accelerate the rate of *JAK2* V617F-driven clonal expansion, the rate can be highly variable even among those without co-mutations as demonstrated at least by the 7 of our 12 patients studied using targeted capture of 41 myeloid genes. Our findings suggest that heritable polymorphisms such as the *JAK2* 46/1 haplotype may have a role,²⁰ but this will need to be confirmed in larger future studies and it is probable that nongenetic factors may also be at play. Our ability to predict clonal growth and by extension forecast the likelihood of progression of *JAK2* V617F clonal hematopoiesis to MPN remains limited, and our study contributes to the understanding of this process. In order to better advise individuals with clonal hematopoiesis of their prognosis and to identify those that could benefit from current or future therapies, larger studies are required to define the variables influencing clonal expansion whether they are heritable vs environmental or cell-intrinsic vs cell-extrinsic and related to the hematopoietic microenvironment.^{21,22}




Figure 1. Preclinical expansion of *JAK2* V617F clones in 12 MPN patients. (A) Schema of blood sample collection from 12 individuals at the time of registration as stem cell donors at the Cyprus Bone Marrow Donor Registry and at the time they were diagnosed with MPN 4.6 to 15.2 years later. (B) Variant allele fraction (VAF) sizes of *JAK2* V617F-positive clones at the 2 time points against the age of participants at the time. The specific diagnosis is indicated in brackets next to each patient's ID, and the average annual rise in *JAK2* V617F VAF is indicated in the upper right quadrant of each plot. Samples P3, P7, and P8 had no detectable *JAK2* V617F at donor registration. The VAF rise for *SRSF2* P95R in patient P3 is shown in red.

The full-text version of this article contains a data supplement.

Acknowledgements: The authors thank Ayalew Tefferi for providing the numbers and age range of individuals with *JAK2* V617F and *SRSF2* P95 co-mutation from his team's recent study of myelofibrosis.¹⁹

This work was supported by the Wellcome Trust Sanger Institute (WT098051). T. McKeirrell is funded by a Wellcome Trust Clinician Scientist Fellowship (100678/Z/12/Z). G.S.V. is funded by a Wellcome Trust Senior Fellowship in Clinical Science (WT095663MA), and work in his laboratory is also funded by Cancer Research UK, Bloodwise, the Kay Kendall Leukaemia Fund, and Celgene. I.V. is

supported by the Spanish Ministerio de Economía y Competitividad, Programa Ramón y Cajal.

Contribution: G.S.V. and P.A.C. designed the study; G.S.V., P.A.C., and T. McKeirrell supervised the study, analyzed data, and wrote the manuscript with contributions from all authors; N.P., T.M., J.C., P.G., and G.C. performed experimental procedures; I.V., T. Moreno, H.P., and J.D. performed bioinformatics analyses; and K.M., C.P., M.A., and P.A.C. contributed to sample and data acquisition.

Conflict-of-interest disclosure: G.S.V. is a consultant for KYMAB and receives an educational grant from Celgene. The remaining authors declare no competing financial interests.

ORCID profiles: T. McKerrell, 0000-0003-4235-0650; G.S.V., 0000-0003-4337-8022.

Correspondence: George S. Vassiliou, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom; e-mail: gsv20@sanger.ac.uk; and Paul A. Costeas, The Karaïskakio Foundation, Nicosia, Cyprus; e-mail: paul.costeas@karaïskakio.org.cy.

References

1. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005;365(9464):1054-1061.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005;7(4):387-397.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med*. 2005;352(17):1779-1790.
4. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434(7037):1144-1148.
5. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. *Hematology Am Soc Hematol Educ Program*. 2014;2014(1):287-296.
6. McKerrell T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell Reports*. 2015;10(8):1239-1245.
7. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
8. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371(26):2477-2487.
9. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med*. 2014;20(12):1472-1478.
10. Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. *Leukemia*. 2013;27(9):1820-1825.
11. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. *Nat Genet*. 2009;41(4):446-449.
12. Hinds DA, Barnholt KE, Mesa RA, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. *Blood*. 2016;128(8):1121-1128.
13. Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. *Haematologica*. 2014;99(9):1448-1455.
14. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med*. 2013;369(25):2391-2405.
15. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. *Nat Commun*. 2016;7:12484.
16. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer [published correction appears in *Nature*. 2013;502(7470):258]. *Nature*. 2013;500(7463):415-421.
17. Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. *Nat Genet*. 2009;41(4):450-454.
18. Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. *Nat Commun*. 2015;6:6691.
19. Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. *Blood Adv*. 2016;1(2):105-111.
20. Vassiliou GS. JAK2 V617F clonal disorders: fate or chance? *Blood*. 2016;128(8):1032-1033.
21. Arranz L, Sánchez-Aguilera A, Martín-Pérez D, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. *Nature*. 2014;512(7512):78-81.
22. McKerrell T, Vassiliou GS. Aging as a driver of leukemogenesis. *Sci Transl Med*. 2015;7(306):306fs38.

DOI 10.1182/bloodadvances.2017007047

© 2017 by The American Society of Hematology